Close Menu

Jimmy Lin

Apr 30, 2019

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.

More Like This

Sep 05, 2019

Farcast Biosciences: Maneesh Arora

Maneesh Arora has joined Boston-based diagnostics firm Farcast Biosciences as president and CEO. Arora previously served as COO and a member of the board of directors of Exact Sciences. He also previously was CFO of Third Wave Technologies, which was acquired in 2008 by Hologic for $582 million. Farcast, formerly called Mitra Biotech, has developed an ex vivo platform for evaluating tumor response to drug treatments.

Aug 26, 2019

Grail: Rodger Currie

Grail has appointed Rodger Currie as VP and head of government affairs and alliance development. Prior to Grail, Currie served as executive VP for advocacy at Pharmaceutical Research and Manufactures of America. Before working at PhRMA, Currie served as VP of global government affairs for Amgen from 2004 to 2010. Prior to Amgen, Currie held multiple roles in government relations at PhRMA. Prior to that, he was majority health counsel to the US House Committee of Energy and Commerce.

Apr 23, 2019

Bahija Jallal

Guardant Health has appointed Bahija Jallal to its board of directors, effective April 17. Jallal has served as the CEO of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that she served as executive VP of AstraZeneca and was president of MedImmune, a subsidiary of AstraZeneca, after holding various other research and development positions at the firm. Jallal is a member of the board of trustees at Johns Hopkins University and of UMB Health Sciences Research Park. She has also served as a past president of the Association for Women in Science.

Apr 23, 2019

Joseph Frendo

Caris Life Sciences announced Joseph Frendo has joined the company as chief operations officer. He was senior vice president of PBM Operations at CVS health. Prior to that, he held various management positions at Medco Health Solutions. In his role at Caris, Frendo will direct technical and clinical staff operations and guide strategies to advance quality and optimize efficiences across the firm, Caris said. 

Apr 18, 2019

Ori Karev

Ori Karev has joined Precipio as chief strategy officer. Karev was formerly CEO of UnitedHealthcare Global, the international division of United Healthcare. He also previously worked for Ernst & Young. An attorney by training, Karev has more than 30 years of experience in the healthcare, insurance, and mobility industries, Precipio said.